Genome Therapeutics, Bristol-Myers deal

Bristol-Myers acquired a non-exclusive license to GENE's PathoGenome

Read the full 85 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE